Prim-O-glucosylcimifugin

Prim-O-glucosylcimifugin
Product Name Prim-O-glucosylcimifugin
CAS No.: 80681-45-4
Catalog No.: CFN98104
Molecular Formula: C22H28O11
Molecular Weight: 468.45 g/mol
Purity: >=98%
Type of Compound: Polyphenols
Physical Desc.: Powder
Targets: TNF-α | NO
Source: The roots of Saposhnikovia divaricata (Turcz.) Schischk.
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Price: $40/20mg
Prim-O-glucosylcimifugin is main medicinal component of the traditional Chinese drug Saposhnikovia divaricata, has inhibition on NO production and DPPH free radical, it can inhibit the proliferation of smooth muscle cell stimulated by TNF-α and increase the proportion of G0/G1 phase.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Phytomedicine.2018, 40:37-47
  • Neurotox Res.2020, 38(1):163-174.
  • Nutrients.2020, 12(11):3448.
  • J Nat Sc Biol Med2019, 10(2):149-156
  • Heliyon2022, 8(2):e08866.
  • Phytochem Anal.2022, doi: 10.1002
  • Phytomedicine.2019, 56:48-56
  • Appl. Sci.2020, 10(8),2804
  • Journal of Functional Foods2022, 91:105019.
  • Molecules.2019, 24(10):E1930
  • Visnagin

    Catalog No: CFN97314
    CAS No: 82-57-5
    Price: $40/20mg
    Norkhellol

    Catalog No: CFN98679
    CAS No: 4439-68-3
    Price: Inquiry(manager@chemfaces.com)
    Angelicain

    Catalog No: CFN98789
    CAS No: 49624-66-0
    Price: Inquiry(manager@chemfaces.com)
    Cimifugin

    Catalog No: CFN98612
    CAS No: 37921-38-3
    Price: $60/20mg
    prim-O-Glucosylangelicain

    Catalog No: CFN97422
    CAS No: 85889-15-2
    Price: Inquiry(manager@chemfaces.com)
    Prim-O-glucosylcimifugin

    Catalog No: CFN98104
    CAS No: 80681-45-4
    Price: $40/20mg
    Monnieriside G

    Catalog No: CFN90981
    CAS No: 1401799-34-5
    Price: $498/5mg
    5-O-Methylvisamminol

    Catalog No: CFN70453
    CAS No: 80681-42-1
    Price: Inquiry(manager@chemfaces.com)
    5-O-Methylvisammioside

    Catalog No: CFN98106
    CAS No: 84272-85-5
    Price: $50/20mg
    6-O-apiosyl-5-O-Methylvisammioside

    Catalog No: CFN90982
    CAS No: 139446-82-5
    Price: $268/5mg
    Zhongguo Zhong Yao Za Zhi. 2008 Sep;33(17):2157-60.
    Effect of prim-o-glucosylcimifugin and 4'-O-beta-D-glucosyl-5-O-methylvisamminol con on proliferation of smooth muscle cell stimulated by TNF-alpha.[Pubmed: 19066065]
    To investigate the effect of Prim-O-glucosylcimifugin and 4'-O-p-D-glucosyl-5-O-methylvisa-mminol con on the proliferation of smooth muscle cell stimulated by TNF-alpha.
    METHODS AND RESULTS:
    The primary cell culture method of smooth muscle cell (SMC) was established by attachment-block. The SMC was identificated by immunochemistry method, and the growth curve was drawn by cytometry. The third generation of SMC was adopted in the experiment. The effect of prim-O-glucosylcimif-ugin and 4'-O-beta-D-glucosyl-5-O-methylvisamminol con on the proliferation and cell cycle of SMC was investigated by MTT and flow cytometry respectively. TNF-alpha of 5 micro g x L(-1) can stimulate the proliferation of SMC and increase the proportion of G2 phase and S phase in cell cycle which has great significant difference (P < 0.01) compared with control. The three dose groups of Prim-O-glucosylcimifugin and 4'-O-beta-D-glucosyl-5-O-methylvisammin-ol con can inhibit the proliferation of SMC and increase the proportion of G0/G1 phase, which has great significant difference (P < 0.01) compared with model group.
    CONCLUSIONS:
    Prim-O-glucosylcimifugin and 4'-O-beta-D-glucosyl-5-O-methylvisamminol con can inhibit the proliferation of SMC stimulated by TNF-alpha.
    Pharmacogn Mag . Jul-Sep 2017;13(51):378-384.
    Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages[Pubmed: 28839360]
    Abstract Background: Radix Saposhnikoviae (RS) exerts anti-inflammatory, analgesic, antipyretic, antioxidation effects and has been used in traditional Chinese medicine to treat common colds, headache, and rheumatoid arthritis. Prim-O-glucosylcimifugin (POG) is the highest content chromone and one of the major active constituents in RS. Objective: The study was aimed to explore the anti-inflammation effects of POG in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. Materials and methods: Cell viability was detected by Cell Counting Kit-8 assay. Production of nitric oxide (NO), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 was assessed by enzyme-linked immunosorbent assay. Real-time polymerase chain reaction and Western blot were performed to analyze mRNA and protein levels, respectively. Results: During the whole experiment, 15, 50, and 100 μg/mL of POG had no cytotoxicity on RAW 264.7 cells. POG dose-dependently inhibited the production of NO, TNF-α, IL-1β, and IL-6 that were induced by LPS. POG treatment downregulated the mRNA and protein expression inducible NO synthase (iNOS) and cyclooxygenase 2 (COX-2) in LPS-activated RAW 264.7 macrophages in a concentration-dependent manner. Furthermore, LPS-induced JAK2/STAT3 activation was prevented in RAW 264.7 macrophages by POG treatment. STAT3 overexpression significantly reversed the effects of POG on LPS-activated RAW 264.7 macrophages. Conclusion: These results demonstrate that POG exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by inhibiting the phosphorylation of JAK2/STAT3. Summary: POG exerts anti-inflammatory effects in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 expression by inhibiting JAK2/STAT3 signaling. Abbreviations used: LPS: Lipopolyssacharide; NO: Nitric oxide; TNF-α: Tumor necrosis factor-α; IL: Interleukin; RS: Radix Saposhnikoviae; POG: Prim-O-glucosylcimifugin; iNOS: Inducible NO synthase; COX2: Cyclooxygenase; FBS: Fetal bovine serum; DMSO: Dimethylsulfoxide; CCK-8: Cell Counting Kit; RIPA: Radio immunoprecipitation assay buffer; ECL: Enhanced chemiluminescence; SD: Standard deviation; ELISA: Enzyme-Linked immunosorbent assay. Keywords: Anti-inflammation; JAK2/STAT3; cytokines; nitric oxide; Prim-O-glucosylcimifugin.
    Zhongguo Zhong Yao Za Zhi. 2014 Dec;39(23):4669-74.
    Studies on effects of calycosin-7-O-β-D-glucoside on prim-O-glucosylcimifugin and cimifugin in vivo pharmacokinetics.[Pubmed: 25911821]
    Study on the effects of Astragali Radix main active flavone calycosin-7-O-β-D-glucoside on Saposhnikoviae Radix main active ingredients Prim-O-glucosylcimifugin and cimifugin, a UPLC-MS/MS method for simultaneous determination of Prim-O-glucosylcimifugin and cimifugin in rat plasma was established, and the comparative pharmacokinetics of Prim-O-glucosylcimifugin and cimifugin after oral administration of Prim-O-glucosylcimifugin and calycosin-7-O-β-D-glucoside-Prim-O-glucosylcimifugin to rats were carried out, which might be conductive in exploring the rationality of Astragali Radix - Saposhnikoviae Radix herb couple. Twelve male SD rats were divided into two groups. Prim-O-glucosylcimifugin and cimifugin in rat plasma of different time points after oral administration of Prim-O-glucosylcimifugin and calycosin-7-O-β-D-glucoside - Prim-O-glucosylcimifugin to rats were determinated. And the main pharmacokinetic parameters were investigated using DAS 3. 2. 4. The established method was rapid, accurate and sensitive for simultaneous determination of Prim-O-glucosylcimifugin and cimifugin in rat plasma. The analysis was performed on a Waters Acquity BEH C18 column (2.1 mm x 100 mm, 1.7 μm) with the mixture of acetonitrile and 0.1% formic acid/water as mobile phase, and the gradient elution at a flow rate of 0.3 mL x min(-1). The analytes were detected by tandem mass spectrometry with the electrospray ionization (ESI) source and in the multiple reaction monitoring (MRM) mode. Compared with Prim-O-glucosylcimifugin group, the AUC(0-t)., and AUC(0-∞) of p-O-glucosylcimifugin as well as the C(max) of cimifugin significantly increased (P < 0.05) in calycosin-7-O-β-D-glucoside-Prim-O-glucosylcimifugin group. Calycosin-7-O-β-D-glucoside could enhance the absorption of Prim-O-glucosylcimifugin and cimifugin and improve the bioavailability, explaining preliminarily the rationality of Astragali Radix-Saposhnikoviae Radix herb couple.
    Planta Med. 2014 Feb;80(2-3):187-92.
    Pharmacokinetic Interaction of astragaloside IV with atractylenolide I and prim-O-glucosylcimifugin in male Sprague Dawley rats.[Pubmed: 24452462]
    Astragaloside IV, atractylenolide I, and Prim-O-glucosylcimifugin are main medicinal components of the traditional Chinese medicine prescription Yu-ping-feng which is composed of three herbs: Astragalus membranaceus, Atractylodes macrocephala, and Saposhnikovia divaricata. This study is aimed to assess the influence of atractylenolide I and Prim-O-glucosylcimifugin on the pharmacokinetic profile of astragaloside IV so as to investigate the pharmacokinetic mechanisms of the Yu-ping-feng prescription.
    METHODS AND RESULTS:
    Fifteen Sprague Dawley rats were randomized to three groups; astragaloside IV, astragaloside IV plus atractylenolide I, and a combination of astragaloside IV, atractylenolide I, and Prim-O-glucosylcimifugin were respectively administered to rats of these three groups via intragastric gavage. Serum samples were collected at different times after drug administration, and serum concentrations of astragaloside IV and atractylenolide I were simultaneously detected using HPLC-electrospray ionization-MS. Compared with administration of astragaloside IV alone, concentrations of astragaloside IV in the serum were significantly increased when it was given in combination with atractylenolide I or atractylenolide I+Prim-O-glucosylcimifugin, with higher values for Cmax (p = 0.019 and p = 0.033 compared with astragaloside IV + atractylenolide I and astragaloside IV + atractylenolide I + Prim-O-glucosylcimifugin groups, respectively) and AUC (p = 0.0052 and p = 0.0047 compared with astragaloside IV + atractylenolide I and astragaloside IV + atractylenolide I + Prim-O-glucosylcimifugin groups, respectively).
    CONCLUSIONS:
    Improvement in mean oral Cmax and mean systemic serum exposure because of the pharmacokinetic interaction between astragaloside IV and atractylenolide I might explain the rationale for the use of multiple herbs in Yu-ping-feng and of combinations of A.membranaceus and A. macrocephala.
    J Asian Nat Prod Res. 2012;14(9):886-96.
    Biotransformation of prim-O-glucosylcimifugin by human intestinal flora and its inhibition on NO production and DPPH free radical.[Pubmed: 22917273]
    Prim-O-glucosylcimifugin (PGCN), a highest content chromone in the roots of Saposhnikovia divaricata, was incubated with human intestinal flora (HIF), and two biotransformation products were obtained from the incubated solution by chromatographic methods.
    METHODS AND RESULTS:
    The chemical structures of the two biotransformation products were elucidated as cimifugin (CN) and 5-O-methylvisamminol (MVL), respectively, on the basis of NMR and MS data. The biotransformation product CN was formed through a deglucosylation of Prim-O-glucosylcimifugin by β-glucosidase secreted from the HIF, and then the hydroxymethyl group of CN was reduced to lead to occurrence of MVL. All of these compounds were evaluated for their effect on the inhibition of nitric oxide production induced by lipopolysaccharide in macrophage cell line RAW 264.7 and for 1,1-diphenyl-2-picrylhydrazyl free-radical scavenging activity in cell-free bioassay system.
    Betmidin

    Catalog No: CFN95047
    CAS No: 35589-22-1
    Price: $413/5mg
    New compound 5

    Catalog No: CFN95258
    CAS No: N/A
    Price: $413/5mg
    6-Hydroxy-7-methoxydihydroligustilide

    Catalog No: CFN95289
    CAS No: 210036-09-2
    Price: $318/5mg
    Corymboside

    Catalog No: CFN95292
    CAS No: 73543-87-0
    Price: $318/10mg
    9-Octadecenedioic acid

    Catalog No: CFN95301
    CAS No: 4494-16-0
    Price: $218/5mg
    Apigenin 6,8-di-C-alpha-L-arabinopyranoside

    Catalog No: CFN95360
    CAS No: 73140-47-3
    Price: $318/10mg
    Maingayone B

    Catalog No: CFN95483
    CAS No: 1071223-57-8
    Price: $318/20mg
    Gossypetin 3-sophoroside-8-glucoside

    Catalog No: CFN95528
    CAS No: 77306-93-5
    Price: $318/5mg
    (3,4-Dihydroxyphenyl)methyl 3-(beta-D-glucopyranosyloxy)-4-hydroxybenzoate

    Catalog No: CFN95531
    CAS No: 877461-90-0
    Price: $318/10mg
    Methyl ganoderenate D

    Catalog No: CFN95572
    CAS No: 748136-03-0
    Price: $413/5mg